S2 Genomics and the RIKEN Center for Integrative Medical Sciences Collaborate on Single-Cell Genomics on Solid Tissues
February 18, 2020
Achieving high-quality single cell data from solid tissues relies upon consistent and reproducible cell or nuclei dissociation procedures. To overcome the challenges often seen with manual cell dissociation methods, S2 Genomics has developed the automated Singulator™ system to process solid tissue samples into suspensions of cells or nuclei for single-cell analysis.
“Current methods of cell isolation are a significant bottleneck for researchers and can lead to inconsistencies in their data. The Singulator™ automates and standardizes the dissociation of solid tissues and can improve the quality of single-cell and single-nuclei data from a variety of solid tissue types,” said Dr. Stevan Jovanovich, President and CEO of S2 Genomics. “We are excited to work with the RIKEN IMS to evaluate the performance of the system and to develop new applications for the Singulator™ platform.”
Dr. Aki Minoda, Unit Leader of the Epigenome Technology Exploration Unit, commented on the collaboration: “We are delighted to collaborate with S2 Genomics and incorporate the Singulator into our workflow for single-cell analyses.”
About S2 Genomics, Inc.
S2 Genomics, founded in 2016, is a leading developer of laboratory automation solutions to process solid tissue for life science applications. S2 Genomics’ technology platforms integrate advanced fluidics, optics, and biochemistry capabilities to produce sample preparation solutions for the next generation sequencing (NGS) and cell biology markets. For more information, visit www.s2genomics.com.
S2 Genomics, the S2 Genomics logo, and Singulator are trademarks of S2 Genomics, Inc.
About the RIKEN Center for Integrative Medical Sciences
The RIKEN IMS aims to elucidate the pathogenesis of human diseases and establish new therapeutic methodologies by conducting cutting-edge research on human genome and immune function. To that end, we have established four Divisions: (1) Division of Genomic Medicine, (2) Division of Human Immunology, (3) Division of Disease Systems Biology, and (4) Division of Next Generation Cancer Immunology. These groups work together to promote state-of-the-art research.
For more information, visit https://www.riken.jp/en/research/labs/ims/index.html.
Media Contact: Dr. John Bashkin, VP Business Development, S2 Genomics, firstname.lastname@example.org
Read full press release here.